

### Analysis of Adverse Event Summary (Safety Analysis Population)

|  | Placebo |        | Xanomeline Low Dose |        | Xanomeline High Dose |        |
|--|---------|--------|---------------------|--------|----------------------|--------|
|  | n       | (%)    | n                   | (%)    | n                    | (%)    |
| Participants in population   | 86      |        | 84                  |        | 84                   |        |
| With any adverse event   | 69      | (80.2) | 77                  | (91.7) | 79                   | (94.0) |
| With drug-related adverse event  | 44      | (51.2) | 73                  | (86.9) | 70                   | (83.3) |
| With serious adverse event   | 0       | (0.0)  | 1                   | (1.2)  | 2                    | (2.4)  |
| With serious drug-related adverse event                                    | 0       | (0.0)  | 1                   | (1.2)  | 1                    | (1.2)  |
| Who died   | 2       | (2.3)  | 1                   | (1.2)  | 0                    | (0.0)  |
| Discontinued due to adverse event  | 0       | (0.0)  | 0                   | (0.0)  | 0                    | (0.0)  |
| Every subject is counted a single time for each applicable row and column. |         |        |                     |        |                      |        |

Source: ADSL and ADAE datasets